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ORIGINAL RESEARCH • MUSCULOSKELETAL IMAGING
Despite the fact that bone is the most common site for metastases from breast cancer (1), standard imaging 
modalities have substantial limitations in the identification 
of metastatic bone disease and assessment of treatment re-
sponse. In Response Evaluation Criteria in Solid Tumors 
version 1.1, bone metastases are considered nonmeasurable 
lesions (2), and increased sclerosis and sclerotic response of 
bone metastases can be difficult to distinguish with CT (3). 
Bone scintigraphy with technetium 99m (99mTc)–methy-
lene diphosphonate often results in underestimation of dis-
ease extent, and difficulties in interpretation of serial bone 
scans are well described (3,4). Fluorine 18 fluorodeoxyglu-
cose (FDG) PET allows for identification of changes in 
metabolic activity related to glucose uptake. Changes in 
maximum FDG standardized uptake value are predictive 
of duration of treatment response and time to progression 
(5,6). However, a proportion of bone metastases can be 
FDG negative and not identifiable at FDG PET imaging 
(7,8).
Recently, there has been renewed interest in the use 
of whole-body MRI with diffusion-weighted sequences 
as a method for assessing malignant disease of bone. 
Whole-body MRI is used to evaluate bone and soft-
tissue disease directly, and there is no requirement for 
injected contrast agents or exposure to ionizing radiation. 
Benign and malignant lesions can be differentiated on the 
basis of differences in cellular density and changes in wa-
ter diffusivity, providing early signs of disease response 
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Background: CT and bone scintigraphy have limitations in evaluating systemic anticancer therapy (SACT) response in bone metasta-
ses from metastatic breast cancer (MBC).
Purpose: To evaluate whether whole-body MRI enables identification of progressive disease (PD) earlier than CT and bone scintig-
raphy in bone-only MBC.
Materials and Methods: This prospective study evaluated participants with bone-only MBC between May 2016 and January 2019 
(ClinicalTrials.gov identifier: NCT03266744). Participants were enrolled at initiation of first or subsequent SACT based on stan-
dard CT and bone scintigraphy imaging. Baseline whole-body MRI was performed within 2 weeks of entry; those with extraosseous 
disease were excluded. CT and whole-body MRI were performed every 12 weeks until definitive PD was evident with one or both 
modalities. In case of PD, bone scintigraphy was used to assess for bone disease progression. Radiologists independently interpreted 
images from CT, whole-body MRI, or bone scintigraphy and were blinded to results with the other modalities. Systematic differ-
ences in performance between modalities were analyzed by using the McNemar test.
Results: Forty-five participants (mean age, 60 years 6 13 [standard deviation]; all women) were evaluated. Median time on study 
was 36 weeks (range, 1–120 weeks). Two participants were excluded because of unequivocal evidence of liver metastases at baseline 
whole-body MRI, two participants were excluded because they had clinical progression before imaging showed PD, and one partic-
ipant was lost to follow-up. Of the 33 participants with PD at imaging, 67% (22 participants) had PD evident at whole-body MRI 
only and 33% (11 participants) had PD at CT and whole-body MRI concurrently; none had PD at CT only (P , .001, McNemar 
test). There was only slight agreement between whole-body MRI and CT (Cohen k, 0.15). PD at bone scintigraphy was reported in 
50% of participants (13 of 26) with bone progression at CT and/or whole-body MRI (P , .001, McNemar test).
Conclusion: Whole-body MRI enabled identification of progressive disease before CT in most participants with bone-only metastatic 
breast cancer. Progressive disease at bone scintigraphy was evident in only half of participants with bone progression at whole-body 
MRI.
© RSNA, 2020
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Study Participants
Participants were recruited as a consecutive series between 
May 2016 and June 2017 at Mount Vernon Cancer Cen-
ter, Northwood, England, and the Royal Marsden Hospital, 
Sutton, England. Imaging was performed until database cut-
off in January 2019. Eligible participants had documented 
bone-only MBC, as established with standard CT and bone 
scintigraphy performed no more than 4 weeks before trial en-
try, and were starting SACT de novo or a new line of SACT. 
Inclusion criteria included a histologic diagnosis of breast 
cancer in patients with single or multiple bone metastases 
without extraosseous or nonbone metastatic disease. Partici-
pants were required to be aged 18 years or older with no other 
current active malignancy and a life expectancy greater than 
6 months. Patients were excluded from the study if they were 
to undergo radical treatment (eg, surgery or stereotactic ra-
diation therapy) to a sole site of metastatic disease. Pregnant 
patients were excluded. The usual contraindications to MRI 
were also applied, including cardiac pacemakers and neuro-
stimulators and marked claustrophobia. Metal implants in 
bone and/or breast prostheses were not a contraindication. 
Baseline whole-body MRI was performed within 2 weeks 
of study entry. No further imaging tests were performed to 
evaluate disease burden, but any additional tests required for 
the initiation of the new SACT, such as blood work-up or 
electrocardiography or echocardiography, were performed ac-
cording to local protocols.
During the study, CT and whole-body MRI were performed 
every 12 weeks (67 days) until PD was evident. If there was 
equivocal evidence of PD at whole-body MRI only, repeat 
whole-body MRI was undertaken 4–6 weeks later to confirm or 
refute the presence of definite PD. If PD was confirmed, then 
the date of progression was defined as that of the whole-body 
MRI examination performed 4–6 weeks earlier. No repeat CT 
examinations were performed in addition to the confirmatory 
whole-body MRI.
The end of the study protocol for an individual participant 
was reached when any of the following occurred: unequivocal 
progressive bone and/or visceral (including lung) disease was 
demonstrated at CT scan and whole-body MRI; unequivocal 
progressive bone and/or visceral disease was demonstrated at 
CT or whole-body MRI alone; or CT and/or whole-body MRI 
findings and/or clinical disease progression necessitated inter-
vention such as palliative radiation therapy or a change in sys-
temic therapy. Repeat bone scintigraphy was performed when 
the participant met one of the end-of-study criteria. Findings 
were compared with those from baseline bone scintigraphy to 
assess for evidence of PD.
Whole-body MRI protocol.—Imaging was performed at both 
centers with a Magnetom Avanto Fit scanner (Siemens Health-
ineers, Erlangen, Germany) by using methods compliant 
with the Metastasis Reporting and Data System for Prostate 
Cancer and the Myeloma Response Assessment and Diag-
nosis System standards for whole-body MRI in bone disease 
evaluations (13,14). Integrated posterior spine and head and 
neck coils were used. Two linked, anterior body 18-coil arrays 
Abbreviations
FDG = fluorine 18 fluorodeoxyglucose, MBC = metastatic breast can-
cer, PD = progressive disease, SACT = systemic anticancer therapy
Summary
In participants receiving systemic anticancer therapy for bone-only 
metastatic breast cancer, whole-body MRI enabled identification of 
progressive disease earlier than whole-body CT and bone scintigra-
phy.
Key Results
 n Whole-body MRI depicted disease progression before CT in 67% 
of participants (22 of 33) with bone-only metastatic breast cancer 
(P , .001), with only slight agreement between the two modali-
ties (k = 0.15).
 n Bone scintigraphy revealed progression in only 50% of partici-
pants (13 of 26) with bone progression identified with whole-body 
MRI (P , .001).
or progression (9). Whole-body MRI is now an established 
tool in the diagnosis and assessment of multiple myeloma 
(10–12), and there are published practical guidelines for 
the acquisition, interpretation, and reporting of whole-body 
MRI scans in patients with multiple myeloma and advanced 
prostate cancer (13,14).
There is limited literature investigating the role of whole-
body MRI in clinical decision making in metastatic breast 
cancer (MBC). Retrospective data show that whole-body MRI 
often depicts sites of disease not evident on CT images, and 
that systemic anticancer therapy (SACT) changes are made 
based on evidence of progressive disease (PD) seen only at 
whole-body MRI in more than one-third of cases (15). There 
is also evidence for the superior performance of whole-body 
MRI compared with FDG PET/CT for SACT response as-
sessment (16).
The primary objective of this prospective study was to evalu-
ate whether whole-body MRI depicts PD earlier than CT and 
bone scintigraphy in bone-only MBC. We hypothesized that 
whole-body MRI would enable identification of PD earlier than 
CT in this patient group.
Materials and Methods
All procedures performed in this study (ClinicalTrials.gov 
identifier: NCT03266744) were in accordance with the 
ethical standards of the National Health Service Health Re-
search Authority East of England–Cambridge East Research 
Ethics Committee and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical standards. 
This work was funded by the Paul Strickland Scanner Cen-
tre Charity (UK registered charity number 298867) and 
Fighting Breast Cancer (UK registered charity number 
1091882). Written informed consent was obtained from all 
participants included in the study. M.L.A. has been an em-
ployee of AstraZeneca UK Limited since April 2018 and is a 
current shareholder. This affiliation does not lead to a direct 
conflict of interest with the presented work. The study pro-
tocol and data generated are available from the correspond-
ing author by request.
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midfemora. Imaging of the chest and abdomen was performed 
in the arterial phase with triggering at the peak arterial phase 
(5 seconds after peak pulmonary artery), and the abdomen 
and pelvis were examined in the portal phase, 35 seconds later. 
Two-millimeter soft-tissue, lung, and bone reconstructions 
were undertaken with appropriate windowing and kernels.
Bone scintigraphy protocol.—Imaging was performed with 
a SKYLight system (Philips, Amsterdam, the Netherlands) 
at Mount Vernon Cancer Center and with a Siemens Intevo 
scanner at the Royal Marsden Hospital; both are dual-headed 
gamma cameras. Imaging was performed between 2.5 and 3 
hours after intravenous injection of 600 MBq of 99mTc–methy-
lene diphosphonate. Only planar imaging in the anterior and 
posterior planes of the whole body was undertaken without 
regional spot views or SPECT reconstructions.
Imaging Evaluation
Objective tumor response was evaluated separately for CT and 
whole-body MRI scans by dedicated oncological radiologists 
were used for coverage of the chest, abdomen, and pelvis to 
the midthighs. Peripheral coils were not used. The following 
sequences were included for whole spine imaging: (a) sagit-
tal T1-weighted turbo spin-echo imaging with 4-mm-thick 
slices in two stations and (b) sagittal short inversion time 
inversion-recovery T2-weighted imaging with 4-mm-thick 
slices in two stations. The following sequences were used for 
whole-body imaging (skull base to midthighs): axial and coro-
nal T1-weighted gradient-recalled echo imaging with a Dixon 
technique with fat percentage reconstructions. The following 
sequences were used for whole-body imaging from vertex to 
midthighs: axial, diffusion-weighted, short inversion time in-
version-recovery imaging with fat suppression, 5-mm contigu-
ous slicing, in four contiguous stations by using b values of 50, 
600, and 900 sec/mm2. Apparent diffusion coefficient calcula-
tions were performed in-line with monoexponential data fit-
ting to the signal intensities of the above b-value images. Other 
reconstructions included coronal multiplanar reconstructions 
(as contiguous two-dimensional 5-mm-thick slices) with a b 
value of 900 sec/mm2 and whole-body three-dimensional max-
imum intensity projection reconstructions with a b value of 
900 sec/mm2 with images displayed as rotating images with 
inverted gray scale. Whole-body (skull base to midthighs) axial 
T2-weighted, turbo spin-echo imaging without fat suppres-
sion, with 5-mm-thick contiguous slices in multiple stations, 
was also performed, matching the diffusion-weighted images. 
Scheduling time was 60 minutes; acquisition time, including 
setup, adjustments, and sequences, was 55 minutes. Full se-
quence parameters can be found in Table E1 (online).
CT protocol.—CT was performed at both study sites with a 
Siemens Somatom Force scanner in dynamic mode. Optiray 
350 (Guerbet, Princeton, NJ) intravenous contrast agent was 
used (75 mL for participants weighing ,80 kg; otherwise, 100 
mL) with the patient in a supine position with arms raised. 
The field of view extended from the midcervical spine to the 
Figure 1: Flowchart shows number of participants recruited and num-
ber and reasons for exclusion from study. PD = progressive disease, SACT = 
systemic anticancer therapy.
Breast Cancer Characteristics and SACT Information for 
Study Participants
Parameter No. of Participants
Histologic finding
 Invasive ductal carcinoma 34 (76)
 Invasive lobular carcinoma 8 (18)
 Mixed 2 (4.4)
 Unknown 1 (2.2)
Grade
 1 4 (8.9)
 2 23 (51)
 3 16 (36)
 Unknown 2 (4.4)
Estrogen receptor status
 Positive 40 (89)
 Negative 5 (11)
 Unknown 0 (0)
HER2 status
 Positive 4 (8.9)
 Negative 41 (91)
 Unknown 0 (0)
Line of SACT (for metastatic breast cancer)
 1 25 (56)
 2 10 (22)
 3 7 (16)
 4 2 (4.4)
 5 1 (2.2)
Type of SACT
 Chemotherapy 12 (27)
 Hormonal therapy 33 (73)
 With HER2-targeted therapy 3 (6.7)
Note.—Data are numbers of participants, with percentages in 
parentheses. The mean age of study participants was 60 years 6 
13 (standard deviation); all participants were women. HER2 = 
human epidermal growth factor 2, SACT = systemic anticancer 
therapy.
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(A.R.P., A.G., or D.M.K.) with more than 10 years of experi-
ence in interpreting whole-body MRI and CT scans. A.R.P. and 
D.M.K. have been involved in the formulation of the whole-
body MRI Metastasis Reporting and Data System for Prostate 
Cancer (13) and Myeloma Response Assessment and Diagnosis 
System (14) guidelines and have led formal training of radiolo-
gists in whole-body MRI. Different readers (A.R.P., A.G., or 
D.M.K.) interpreted the whole-body MRI and CT scans. Bone 
scintigraphy findings were reported by separate nuclear medicine 
radiologists. The MRI and CT readers were blinded to the imag-
ing results of the other modality; the bone scintigraphy reader 
was aware of the presence of PD. Imaging evaluations were done 
at the patient level with no separate analyses by sequence or ana-
tomic region. Details of the imaging criteria for disease response 
evaluation can be found in Appendix E1 (online).
Statistical Design
This nonrandomized study was designed to detect a superiority 
in performance of whole-body MRI versus CT in the identi-
fication of first PD. With use of an A’Hern single-stage phase 
II procedure with 90% power and a one-sided a of .05, 33 
evaluable participants were required in order to determine an 
improvement in identification of first PD by means of whole-
body MRI from 50% to 75% of participants. Statistical analy-
sis comparing the proportion of first PD identified by means 
of whole-body MRI alone versus CT alone versus concurrent 
PD in both modalities was performed by using the McNemar 
test to detect systematic differences in performance. The Co-
hen k test was used to evaluate the overall level of agreement 
between whole-body MRI and CT. Database cutoff occurred 
when all enrolled participants had been in the study for at least 
36 weeks or had reached the end of the aforementioned study 
protocol. P , .05 was considered to indicate a statistically sig-
nificant difference in all tests. Statistical analysis was performed 




Forty-five participants were recruited (Fig 1). The mean age 
of all participants was 60 years (standard deviation, 13 years; 
Figure 2: Images show differences between whole-body MRI, CT, and bone 
scintigraphy in depicting sites of bone progression in 59-year-old woman with estro-
gen receptor–positive, human epidermal growth factor receptor 2–negative grade 1 
invasive ductal carcinoma. The patient was receiving fulvestrant as third-line systemic 
anticancer therapy for metastatic breast cancer. Baseline imaging was performed in 
in August 2016 (time point 1 [TP1]); response assessment imaging was performed 
in March 2017 (time point 2 [TP2]). Coronal high-signal-intensity inverted maximum 
intensity projection (MIP) images obtained with whole-body MRI show progressive 
disease (PD) at multiple bone sites (arrows). Progression at these sites is not apparent 
on scans obtained at bone scintigraphy (BS) (anterior planar view). PD is also evi-
dent on axial MRI scans obtained through the sacrum with b value of 900 sec/mm2 
(b900). Changes in mineralization on axial CT images through sacrum do not meet 
criteria for PD.
Kosmin et al
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all women). Most participants 
(56%; 25 of 45 participants) 
were enrolled at the point of 
initiation of first-line SACT 
for MBC. A summary of the 
breast cancer characteristics 
and SACTs of the participants 
is shown in the Table.
Of the 33 participants re-
ceiving hormonal therapy, four 
received additional ovarian sup-
pression with goserelin. One 
participant started everolimus 
alongside exemestane. Three 
participants received cyclin-de-
pendent kinase 4 and 6 inhibi-
tors (two received palbociclib; 
one received ribociclib) with 
aromatase inhibitors. Of the 
three participants receiving hu-
man epidermal growth factor 
receptor 2–targeted therapy, one 
received trastuzumab emtansine, 
one received trastuzumab with 
capecitabine, and one received 
trastuzumab with exemestane.
Of the 45 participants, two 
(4.4%) with bone-only disease 
at CT and bone scintigraphy be-
fore trial entry had unequivocal 
evidence of liver metastases on 
their baseline whole-body MRI 
scans. Their involvement in the 
study ceased at that point. Two 
participants (4.4%) had clinical 
PD requiring SACT change be-
fore evidence of PD at study im-
aging. One participant moved 
abroad and was classified as lost 
to follow-up. A total of 129 
pairs of CT and whole-body 
MRI scans were performed for 
response assessment. Median 
participant time on study was 
36 weeks (range, 1–120 weeks).
At the time of database cut-
off, the remaining 40 partici-
pants had either met the primary 
end point of PD at imaging (n = 
33) or continued with the SACT 
initiated at trial entry with no ev-
idence of PD at their most recent 
imaging time point (n = 7). The 
median time to reported PD was 
24 weeks (range, 12–84 weeks). 
One participant required early 
reassessment whole-body MRI 
Figure 3: Images show disease progression in bone and liver seen only at whole-body MRI in 36-year-old woman with 
estrogen receptor–positive, human epidermal growth factor receptor 2–negative grade 3 invasive ductal carcinoma. The 
patient was receiving eribulin chemotherapy and denosumab as fourth-line systemic anticancer therapy for metastatic breast 
cancer. Baseline imaging was performed in August 2016 (time point 1 [TP1]); response assessment imaging was performed 
in February 2017 (time point 2 [TP2]). Evidence of progressive disease of bone lesion in T5 vertebral body is seen on axial 
high-signal-intensity (b value, 900 sec/mm2) whole-body MRI scan (b900); however, no change is seen in CT image at 
level of T5. Multiple new liver lesions (arrows) are evident on axial MRI scan obtained with b value of 900 sec/mm2 but do 
not appear on CT image.
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Figure 4: Images show 
discordance between bone 
scintigraphy and whole-
body MRI in 36-year-old 
woman with estrogen 
receptor–positive, human 
epidermal growth factor re-
ceptor 2–negative grade 3 
invasive ductal carcinoma. 
The patient was receiving 
eribulin chemotherapy and 
denosumab as fourth-line 
systemic anticancer ther-
apy for metastatic breast 
cancer. Baseline imaging 
was performed in August 
2016 (time point 1 [TP1]); 
response assessment im-
aging was performed in 
February 2017 (time point 
2 [TP2]). Coronal images 
from bone scintigraphy 
(top) and inverted maxi-
mum intensity projection 
images obtained with a b 
value of 900 sec/mm2 at 
whole-body MRI (bottom) 
are shown. Whole-body 
MRI scan at response as-
sessment imaging shows 
evidence of progressive 
disease at multiple bone 
sites (arrows). Image from 
bone scintigraphy does not 
show disease progression 
at these locations.
Kosmin et al
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owing to equivocal changes of possible PD seen at whole-body 
MRI alone. In this case, repeat whole-body MRI performed 31 
days later confirmed PD.
PD at Whole-Body MRI, CT, and Bone Scintigraphy
Among the 33 participants with PD at imaging, PD was evi-
dent only on whole-body MRI scans in 22 (67%). The remain-
ing 11 participants (33%) had PD evident on both CT and 
whole-body MRI scans at the same time point. There were no 
participants with PD at CT alone. All 40 participants who met 
the primary end point of the study or who were still enrolled 
at database cutoff were included in the McNemar analysis. The 
contingency table incorporated the following groups: PD at 
both whole-body MRI and CT (n = 11); PD at whole-body 
MRI alone (n = 22); PD at CT alone (n = 0); and PD at nei-
ther whole-body MRI nor CT (n = 7). Performance between 
CT and whole-body MRI differed in identification of PD (P 
, .001, McNemar test). The Cohen k statistic was 0.15 (95% 
confidence interval: 0.02, 0.27), suggesting only slight agree-
ment between whole-body MRI and CT.
Of the 33 participants with PD at imaging, 25 (76%) had 
bone-only progression, five (15%) had PD in bone and at ex-
traosseous sites concurrently (three with new liver metastases, 
two with new metastatic nodal disease), and three (9.1%) had 
extraosseous PD alone (one participant had liver-only PD; one 
had liver and lung PD; one had brain-only PD). Of the 22 par-
ticipants in whom PD was seen only at whole-body MRI, 18 
had bone-only PD (Fig 2), two had bone and liver PD (Fig 3), 
and two had extraosseous PD (one liver only, one brain only).
Of the 26 end-of-study bone scintigraphy procedures per-
formed when there was PD in bone at CT and/or whole-body 
MRI, progression at bone scintigraphy was reported in 13 (50%) 
(P , .001, McNemar test). An example case of PD at whole-
body MRI without PD at bone scintigraphy is shown in Figure 
4. PD was not reported at bone scintigraphy in the three partici-
pants with extraosseous progression.
Overall, only 21% of participants (six of 29) had evidence of 
PD with all three modalities (whole-body MRI, CT, and bone 
scintigraphy). Forty-one percent of participants (12 of 29) had 
PD evident at whole-body MRI only; 14% (four of 29) had PD 
at whole-body MRI and CT only; and 24% (seven of 29) had 
PD at whole-body MRI and bone scintigraphy only.
Discussion
Clinical management of patients with bone-only metastatic 
breast cancer (MBC) has been limited by the inability of bone 
scintigraphy and CT to reliably and accurately enable identifi-
cation of progressive disease (PD). In our prospective study in 
which whole-body MRI and CT were compared for response 
assessment in patients with bone-only MBC, whole-body MRI 
enabled identification of PD before CT in 67% of participants 
(P , .001, McNemar test). Evidence of PD at bone scintigra-
phy was found in only 50% of participants with PD in bone 
identified with whole-body MRI (P , .001, McNemar test), 
providing further evidence of the poor performance of bone 
scintigraphy as a tool for response assessment in MBC. Lev-
els of participant-reported tolerability and compliance with 
whole-body MRI were high in our trial, even after multiple 
scanning episodes.
There were several potential mechanisms for the differences 
in performance between the imaging modalities evaluated in 
this study. Unlike whole-body MRI, CT and bone scintigraphy 
are used to evaluate the bone matrix response to the presence 
of cancer cells rather than the metastatic foci themselves, mean-
ing that they are indirect reporters of malignant bone marrow 
pathologic features. Progression within metastatic foci is there-
fore detectable with CT and bone scintigraphy only when there 
has been an appreciable change in the surrounding bone struc-
ture. In bone scintigraphy, detection of bone metastases is reliant 
on increased osteoblast activity in the vicinity of the metastases, 
which results in differential tracer accumulation at sites of min-
eral deposition. With CT, changes in bone mineralization due to 
disease progression causing bone destruction and/or new bone 
formation must become perceptible before PD can be identified 
(3). This limits the sensitivity of these modalities for assessing the 
response of bone metastases to treatment. Whole-body MRI en-
ables direct evaluation of metastatic lesions in the bone marrow 
space, with changes in water diffusivity reflecting changes in cel-
lularity within lesions and displacement of marrow fat providing 
earlier signs of disease progression (9).
Earlier identification of progression of MBC in bone may 
allow switching from a failing systemic therapy sooner, po-
tentially facilitating better control of disease over time. Use of 
whole-body MRI may help identify patients at particular risk of 
symptomatic skeletal events such as metastatic spinal cord and/
or cauda equina compression, pathologic fractures, and sites of 
bone pain necessitating palliative radiation therapy (17). How-
ever, it remains unclear whether earlier identification of disease 
progression with whole-body MRI and earlier change in SACT 
can lead to improved outcomes (eg, reduced rates of symptom-
atic skeletal events) in MBC. To our knowledge, there are no 
published data on the prognostic importance of the change in 
disease burden through multiple lines of SACT in MBC.
This study was limited by enrolling only patients with bone-
only MBC. We therefore cannot comment on whether other 
patient subgroups (eg, those with locally advanced or nodal or 
visceral disease) would benefit equally from the use of whole-
body MRI. We did not evaluate the disease detection sensitiv-
ity according to MRI sequence type, as our aim was to perform 
a patient-level analysis. Such analyses have been performed by 
other investigators for myeloma and prostate cancer (18). Our 
study was limited by the small number of participants and the 
use of different bone scintigraphy equipment at the two centers. 
However, CT and MRI equipment was identical, and common 
quality assurance and quality control procedures were in place 
for the two participating centers for both modalities. Another 
limitation of this study was the use of confirmatory whole-
body MRI (but not CT) in cases of equivocal progression seen 
at whole-body MRI only 4–6 weeks earlier. However, this was 
undertaken in only one participant and is unlikely to alter the 
study findings.
Further investigation of whole-body MRI is required to es-
tablish whether its use as a SACT response assessment tool in pa-
tients with bone metastases from breast cancer improves clinical 
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outcomes, such as a reduction in the rate of symptomatic skeletal 
events. The development of consensus guidelines for the acquisi-
tion, interpretation, and reporting of whole-body MRI in MBC 
would deal with the current lack of widely recognized criteria 
for assessment of bone disease in MBC, although guidelines do 
exist for metastatic prostate cancer (13) and for multiple my-
eloma (14). Such guidelines would enable patients with bone-
only MBC to enter future clinical trials of promising anticancer 
therapeutics through use of whole-body MRI for more accurate 
and reliable assessment of their bone disease status.
In conclusion, whole-body MRI enabled identification of 
progressive disease (PD) before CT in most participants with 
bone-only metastatic breast cancer. PD at bone scintigraphy 
was evident in only half of participants with bone progression 
at whole-body MRI.
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